MANKIND PHARMA IPO- 7 FACTS ABOUT THE COMPANY YOU SHOULD KNOW
Mankind Pharma, India's fourth largest pharmaceutical company is all set to make its debut on the stock market with its maiden public offer in order to raise Rs 4,326 crore on 25th April 2023. So Here are 7 facts about the company that you should know:
COMPANY
Mankind Pharma is the fourth-largest Pharmaceutical company in India and third-largest in terms of sales volume ( as per IQVIA MAT Dec 2022). With this IPO to raise Rs 4,326 crore, the company is looking at a valuation of Rs 43,624 crore. Mankind has the largest network of medical representatives in India, a major reason behind its substantial growth.
FOUNDERS
Mankind Pharma was founded by Rajeev Juneja and his older brother Ramesh Juneja in the year 1995 with funds of Rs 50 lakhs and a team of 25 medical reps. Before founding Mankind Pharma, Ramesh Juneja had worked with various pharma companies, starting as a medical representative and rising up to marketing positions. Domestic Sales account for more than 95% of the sales of the company.
PURPOSE AND IDEOLOGY
The purpose behind this was to have a pharma company that provides low-cost pharma generics, mainly to the Indian population. The company offers products at very low prices compared to many other pharma companies, and this has been the main reason behind the substantial growth of Mankind Pharma.
SPECIALIZATION PRODUCTS
The company primarily makes generic products. It specializes in the areas of anti-infectives, gastrointestinal disorders, gynaecology, cardiovascular disorders, psychiatry disorders, dermatology and erectile dysfunction.
TOP PRODUCTS
Some of its top products of Mankind Pharma include MOXIKIND-CV, MANFORCE, CANDIFORCE, AMLOKIND-AT, UNWANTED-KIT, GLIMESTAR-M, GUDCEF, PREGA NEWS, NUROKIND PLUS-RF, NUROKIND-LC, NUROKIND-GOLD, TELMIKIND-H, TELMIKIND.
MANUFACTURING FACILITIES
Mankind Pharma has manufacturing facilities all over the country located in Himachal Pradesh, Sikkim, Rajasthan, Andhra Pradesh and Uttrakhand. It has an international presence in Asia, Africa, CIS and South-East Asia.
IPO OFFER
The company issue will open on April 25th 2023 and close on April 27, 2023, on both NSE and BSE. The size of the issue is 4,326.4 crore and the face value of a share is Re 1 a piece. The lot size is set at 13 equity shares and multiples. The company has set aside 35% of the net offer for individual investors, 50% for qualified institutional buyers, and 15% for non-institutional buyers. and Post the issue promoter holding will be 76.5%.